We are monitoring the impact of COVID-19 on MEA Cancer Metabolism Based Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 7871
Share on
Share on

Middle East and Africa Cancer Metabolism Based Therapeutics Market Research Report – Segmented By Therapy, Drug Type, Indication & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) – Industry Size, Share, Trends & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 7871
Pages: 145

The size of the Middle East and Africa Cancer Metabolism Based Therapeutics Market is forecasted to grow at a sluggish rate between 2021 to 2026.  

The hike in this market is driven by several factors, some of them include an increase in the number of people who are diagnosed with cancer every year, smoking tobacco, exposing the body to different types of radiations, heredity, chemicals. Introducing new ways of treating cancers also increasing the market share. The high cost of treatment may drag back the market value in some of the developing countries.

The market is segmented by Therapy, Drug type, and Indication. By therapy, the market is categorized into Biological drug therapies and Targeted drug therapies. By drug type, the market is further divided into CPI-613, Enasidenib, others. CPI-613 was introduced recently in 2018 which is considered as the best drug to treat pancreatic cancer. Enasidenib also got its importance in treating pancreatic cancer. According to a report from American Cancer Society in 2018, 53 thousand people were diagnosed with pancreatic cancer and around 43 thousand of them are experiencing a threat to their lives. By Indication, the market is segregated into Melanoma, Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), Metastatic Renal Cell Carcinoma, and others. Around twenty one thousand cases of Acute Myeloid Leukemia attacks were reported by American Cancer Society in 2018, out of which 50% are experiencing the terminal stage. Many non-profit organizations came into the picture to help people and increased awareness about symptoms and treatment process of pancreatic cancer which is helping the market to increase its size.

By geography, the market is segmented into the countries of the Middle East and Africa. Countries like UAE and South Africa occupy the major market size.

Some of the prime manufacturers of Cancer Metabolism Based Therapeutics in the Middle East and Africa are AstraZeneca, Novartis, Celgene, Rafael Pharmaceuticals, Cornerstone Pharmaceuticals, Polaris Group, Agios Pharmaceuticals, Taiho Pharmaceuticals, 3-V biosciences, Calithera Biosciences, and BERG Health.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Therapy                       

                                5.1.1 Introduction           

                                5.1.2 Biological Drug Therapies  

                                5.1.3 Targeted Drug Therapies  

                                5.1.4  Y-o-Y Growth Analysis, By Therapy              

                                5.1.5  Market Attractiveness Analysis, By Therapy            

                                5.1.6  Market Share Analysis, By Therapy             

                5.2 Drug Type                   

                                5.2.1 Introduction           

                                5.2.2 Enasidenib              

                                5.2.3 CPI-613     

                                5.2.4 Other Drugs            

                                5.2.5 Y-o-Y Growth Analysis, By Drug Type           

                                5.2.6 Market Attractiveness Analysis, By Drug Type         

                                5.2.7 Market Share Analysis, By Drug Type          

                5.3 Indication                    

                                5.3.1 Introduction           

                                5.3.2 Melanoma              

                                5.3.3 Myelodyspalstic Syndrome (MDS)

                                5.3.4 Acute Myeloid Leukemia (AML)    

                                5.3.5 Metastatic Renal Cell Carcinoma    

                                5.3.6 Others      

                                5.3.7 Y-o-Y Growth Analysis, By Indication           

                                5.3.8 Market Attractiveness Analysis, By Indication         

                                5.3.9 Market Share Analysis, By Indication           

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Therapy

                                                6.1.3.3 By Drug Type

                                                6.1.3.4 By Indication

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Therapy

                                                6.1.4.3 By Drug Type

                                                6.1.4.4 By Indication

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Therapy

                                                6.1.5.3 By Drug Type

                                                6.1.5.4 By Indication

                6.2 Middle-East                                

                6.3 Africa                            

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 AstraZeneca                               

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Novartis                       

                8.3 Celgene                       

                8.4 Rafael Pharmaceuticals                         

                8.5 Cornerstone Pharmaceuticals                            

                8.6 Polaris Group                             

                8.7 Agios Pharmaceuticals                           

                8.8 Taiho Pharmaceuticals                           

                8.9 3-V Biosciences                         

                8.10 Calithera Biosciences                           

                8.11 BERG Health                            

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of Therapy, by  Drug type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

                                                                                                                          

  1. Middle East and Africa Cancer Metabolism Based Therapeutics Market, By Therapy, From 2021 to 2026 (USD Million)
  2. Middle East and Africa Biological Drug Therapies Market, By Region, From 2021 to 2026 (USD Million)
  3. Middle East and Africa Targeted Drug Therapies   Market, By Region, From 2021 to 2026 (USD Million)
  4. Middle East and Africa Cancer Metabolism Based Therapeutics Market, By Drug Type, From 2021 to 2026 (USD Million)
  5. Middle East and Africa Enasidenib         Market, By Region, From 2021 to 2026 (USD Million)
  6. Middle East and Africa CPI-613 Market, By Region, From 2021 to 2026 (USD Million)
  7. Middle East and Africa Other Drugs Market, By Region, From 2021 to 2026 (USD Million)
  8. Middle East and Africa Cancer Metabolism Based Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  9. Middle East and Africa Melanoma Market, By Region, From 2021 to 2026 (USD Million)
  10. Middle East and Africa Myelodyspalstic Syndrome (MDS) Market, By Region, From 2021 to 2026 (USD Million)
  11. Middle East and Africa Acute Myeloid Leukemia (AML) Market, By Region, From 2021 to 2026 (USD Million)
  12. Middle East and Africa Metastatic Renal Cell Carcinoma Market, By Region, From 2021 to 2026 (USD Million)
  13. Middle East and Africa Others       Market, By Region, From 2021 to 2026 (USD Million)
  14. Middle East Cancer Metabolism Based Therapeutics Market, By Therapy, From 2021 to 2026 (USD Million)
  15. Middle East Cancer Metabolism Based Therapeutics Market, By Drug Type, From 2021 to 2026 (USD Million)
  16. Middle East Cancer Metabolism Based Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  17. Africa Cancer Metabolism Based Therapeutics Market, By Therapy, From 2021 to 2026 (USD Million)
  18. Africa Cancer Metabolism Based Therapeutics Market, By Drug Type, From 2021 to 2026 (USD Million)
  19. Africa Cancer Metabolism Based Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample